ArticleHIV medicine2026
HIV-1 viral load and reservoir size remain stable following SARS-CoV-2 mRNA vaccination in people with HIV.
Article in HIV medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dynamics of HIV reservoirs following repeated anti-SARS-CoV-2 vaccination.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe potent immunogenicity of mRNA vaccination raised concerns about its impact on HIV-1 viral load (VL) and reservoir size in people with HIV, which could drive vaccine hesitancy. As part of a prospective clinical trial, we investigated whether SARS-CoV-2 mRNA vaccination induced changes in VL and reservoir size after a 1-year three-dose regimen in people with HIV on antiretroviral therapy (ART).
methodsWe collected blood samples from 37 people with HIV with varying degrees of immune reconstitution before vaccination and after receiving their second and third doses of vaccine. Anti-SARS-CoV-2-Spike antibodies and Spike-specific CD4
resultsVaccination with three doses of SARS-CoV-2 mRNA vaccine over the course of 1 year did not result in plasma HIV-1 RNA rebound nor significantly alter the HIV-1 reservoir size regardless of immune status. The median intact HIV-1 reservoir size was 53 (IQR 34-193) copies/million CD4
conclusionsOur findings show that three doses of SARS-CoV-2 mRNA vaccine did not affect the VL or HIV reservoir size regardless of immune status, supporting their safety in people with HIV. Notably, a higher CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.